Jeffrey W. Albers - Insider Trading & Ownership

Entity
Individual
Location
Blueprint Medicines Corp., 215 First Street, Suite 340/350, Cambridge, MA
Summary
The estimated net worth of Jeffrey W. Albers is at least $21.6M dollars as of January 23, 2025. Jeffrey W. Albers is the Director of Blueprint Medicines Corp and owns shares of Blueprint Medicines Corp (BPMC) stock worth about $20.6M. Jeffrey W. Albers is the Director of Spyre Therapeutics, Inc. and owns shares of Spyre Therapeutics, Inc. (SYRE) stock worth about $1.01M.
All Insider Reports
All Insider Reports

Ownership of Jeffrey W. Albers

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
BPMC Blueprint Medicines Corp Director $20.6M -$8.9M -30.1% Jan 21, 2025
SYRE Spyre Therapeutics, Inc. Director $1.01M -$257K -20.4% Nov 6, 2024
KYMR Kymera Therapeutics, Inc. Director $0 -$441K -100% Aug 26, 2024
DNTH Dianthus Therapeutics, Inc. /DE/ Director Jun 28, 2022

Insider Transactions Reported by Jeffrey W. Albers:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.